Table 2.
Dry eye disease ion transport therapies
| Therapy name | Mechanism of action | Clinical trial |
Relevant references | |
|---|---|---|---|---|
| Identifier | Phase | |||
| Diquafosol | Purinergic P2Y2 receptor agonist | NCT04668118 | 4 | [8••, 33, 34•, 35••, 36–49] |
| Tivanisiran (SYL1001) | siRNA TRPV1 inhibitor | NCT04819269 | 3 | [35••, 50, 51] |
| ALY688 | Adiponectin receptor agonist | NCT04899518 | 3 | [52–54] |
| RGN-259 (Tb4) | ATP-responsive purinergic receptor P2X4 agonist | NCT03937882 | 3 | [35••, 55–57] |
| VSJ-110 | CFTR activator | NCT04622345 | 2 | [22•, 23–25] |
| P-321 (SHP-659) | ENaC inhibitor | NCT02824913, NCT02831387 | 2 | [32, 58•] |
| AR-15512 | TRPM8 agonist | NCT04498182 | 2 | [59–63•] |
| Cact-3 | CFTR activator | NA | NA | [64•] |
| Isorhamnetin | CFTR activator | NA | NA | [65•] |
| Cryosim-3 (C3) | TRPM8 agonist | NA | NA | [8••, 61] |
| Pituitary Adenylate Cyclase-Activating Peptide (PACAP) | Increases cAMP, PKA, and AQP-5 | NA* | NA* | [8••, 66, 67•, 68–70] |
| 2-Guanidine-4-Methylquinazoline (GMQ) | ASIC3 agonist | NA | NA | [8••, 71] |
*
No DED-related clinical trial